These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1653186)

  • 41. Captopril inhibits peptidylglycine- alpha-hydroxylating monooxygenase: implications for therapeutic effects.
    Mueller SA; Driscoll WJ; Mueller GP
    Pharmacology; 1999 May; 58(5):270-80. PubMed ID: 10087468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypomagnesemia and isoproterenol cardiomyopathies: Protection by probucol.
    Atrakchi AH; Bloom S; Dickens BF; Mak IT; Weglicki WB
    Cardiovasc Pathol; 1992; 1(2):155-60. PubMed ID: 25990127
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.
    Pasini AF; Garbin U; Nava MC; Stranieri C; Pellegrini M; Boccioletti V; Luchetta ML; Fabrizzi P; Lo Cascio V; Cominacini L
    Am J Hypertens; 2007 Apr; 20(4):443-50. PubMed ID: 17386354
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Design, synthesis and enzyme inhibitory activities of new trifluoromethyl-containing inhibitors for angiotensin converting enzyme.
    Ojima I; Jameison FA; Pete B; Radunz H; Schittenhelm C; Lindner HJ; Emith AE
    Drug Des Discov; 1994 Feb; 11(2):91-113. PubMed ID: 8075303
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An attempt to assess the central action of captopril and enalaprilat.
    Czarnecka E; Strzelec J; Pietrzak B
    Med Sci Monit; 2000; 6(3):491-7. PubMed ID: 11208359
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effect of sublingual captopril versus intravenous enalaprilat on angiotensin II plasma levels.
    van Onzenoort HA; Bussink M; Menheere PP; van Mook WN; van der Kuy PH
    Pharm World Sci; 2006 Jun; 28(3):131-4. PubMed ID: 17004021
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension.
    Napoli C; Sica V; de Nigris F; Pignalosa O; Condorelli M; Ignarro LJ; Liguori A
    Am Heart J; 2004 Jul; 148(1):e5. PubMed ID: 15215814
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An Angiotensin-converting enzyme inhibitor, zofenopril, prevents renal ischemia/reperfusion injury in rats.
    Altunoluk B; Soylemez H; Oguz F; Turkmen E; Fadillioglu E
    Ann Clin Lab Sci; 2006; 36(3):326-32. PubMed ID: 16951275
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids.
    Kowala MC; Grove RI; Aberg G
    Atherosclerosis; 1994 Jul; 108(1):61-72. PubMed ID: 7980708
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effects of bradykinin and the ischemic isolated rat heart.
    Tio RA; van Gilst WH; Rett K; Wolters K; Dietze GJ; Wesseling H
    Horm Metab Res Suppl; 1990; 22():85-9. PubMed ID: 2167866
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of captopril, enalaprilat and mercaptopropionyl glycine (MPG) on the oxidative activity of human isolated neutrophils.
    Clapperton M; Beswick PH; Abdullah I; Dargie HJ; Fisher AC; McMurray J
    Br J Clin Pharmacol; 1995 Jul; 40(1):31-5. PubMed ID: 8527265
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Angiotensins and the failing heart. Enhanced positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril.
    Hirakata H; Fouad-Tarazi FM; Bumpus FM; Khosla M; Healy B; Husain A; Urata H; Kumagai H
    Circ Res; 1990 Apr; 66(4):891-9. PubMed ID: 2180588
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice.
    Sarro GD; Paola ED; Gratteri S; Gareri P; Rispoli V; Siniscalchi A; Tripepi G; Gallelli L; Citraro R; Russo E
    Pharmacol Res; 2012 Mar; 65(3):285-96. PubMed ID: 22107891
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril.
    Evangelista S; Manzini S
    J Int Med Res; 2005; 33(1):42-54. PubMed ID: 15651714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-free radical mechanisms in captopril protection against reperfusion injury in isolated rat hearts.
    Anderson B; Khaper N; Dhalla AK; Singal PK
    Can J Cardiol; 1996 Oct; 12(10):1099-104. PubMed ID: 9191504
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension.
    Napoli C; Bruzzese G; Ignarro LJ; Crimi E; de Nigris F; Williams-Ignarro S; Libardi S; Sommese L; Fiorito C; Mancini FP; Cacciatore F; Liguori A
    Am Heart J; 2008 Dec; 156(6):1154.e1-8. PubMed ID: 19033012
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measurement of angiotensin I converting enzyme inhibition in the heart.
    Kinoshita A; Urata H; Bumpus FM; Husain A
    Circ Res; 1993 Jul; 73(1):51-60. PubMed ID: 8389676
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhibition of angiotensin-converting enzyme in human hand veins.
    Chalon S; Bedarida GV; Moreno H; Tejura B; Urae A; Hoffman BB; Blaschke TF
    Clin Pharmacol Ther; 1999 Jan; 65(1):58-65. PubMed ID: 9951431
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prolongation by captopril of action potential duration in the normal and hypertrophied rat ventricle: direct action or inhibition of the local angiotensin converting enzyme?
    Ribuot C; Cardinal R; Gouin L; Moreau P; Godin D; Vermeulen M; de Champlain J; Rochette L; Nadeau R
    Cardiovasc Res; 1994 Feb; 28(2):221-7. PubMed ID: 8143304
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro.
    Persson K; Whiss PA; Nyhlén K; Jacobsson-Strier M; Glindell M; Andersson RG
    Eur J Pharmacol; 2000 Oct; 406(1):15-23. PubMed ID: 11011027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.